SCHEMBL23958752

SCHEMBL23958752

CC(C)(O)c1cc(-c2ccc(F)cc2)nc(C(O)(CN)C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.41
TP53 P04637 6/20 0.37
MAPT P10636 4/20 0.37
ALDH1A1 P00352 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPSR1 Q6W5P4 3/20 0.37
LMNA P02545 2/20 0.37
TLR9 Q9NR96 2/20 0.37
MITF O75030 1/20 0.37
STAT3 P40763 1/20 0.37
STAT1 P42224 1/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
TNKS O95271 2/20 0.36
PARP1 P09874 2/20 0.36
TNKS2 Q9H2K2 2/20 0.36
TDP1 Q9NUW8 2/20 0.35
MAPK1 P28482 4/20 0.34
HSD17B10 Q99714 4/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25687015 1.00 KDM4E (0.41) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL25687018 1.00 KDM4E (0.41) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL25687152 0.93 KDM4E (0.41) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL31412355 0.91 KDM4E (0.40) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL31412381 0.86 KDM4E (0.40) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL18054809 0.82 TP53 (0.39) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL16533498 0.82 TP53 (0.39) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL25422424 0.82 TP53 (0.40) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL23930189 0.80 ALDH1A1 (0.40) KDM4ETP53MAPTALDH1A1SMN1; SMN2
SCHEMBL30211277 0.80 ALDH1A1 (0.40) KDM4ETP53MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE KDM4E 3733/4885TP53 4179/4885MAPT 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.